drug
Wegovy Pill
Marketedupdated 6mo agoby Novo Nordisk Inc
Approvedannual revenue · 2024–2024peak $8.4B
community read0 votes
🐶 often sniffed alongside
top 8- drugOzempic168 co-mentions · 74 sources
- drugWegovy168 co-mentions · 74 sources
- tagApproval124 co-mentions · 44 sources
- drugRybelsus94 co-mentions · 72 sources
- drugsemaglutide94 co-mentions · 72 sources
- tagRecall33 co-mentions · 27 sources
- companyNovo Nordisk Inc22 co-mentions · 3 sources
- tagSmall Molecule22 co-mentions · 18 sources
Protein drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 30 investigational indications.
indications
investigational
Obesity
all catalysts(2)
Trials studying Wegovy Pill
- phase3AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- phase1Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants
- phase3A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- phase4Semaglutide vs Sitagliptin
- phase3A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
- phase3A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
- phase3A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
- phase1A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 8, 2027
109 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (165)
- Feb 17, 2041formulationUS 11318191
- Feb 17, 2041formulationUS 11318191
- Feb 17, 2041formulationUS 11318191
- Feb 17, 2041formulationUS 11318191
- Feb 17, 2041formulationUS 11318191
- Feb 17, 2041formulationUS 11318191
- May 13, 2040method-of-use (U-3861)US 11478533
- May 13, 2040method-of-use (U-3861)US 11478533
- May 13, 2040method-of-use (U-3861)US 11478533
- May 13, 2040method-of-use (U-3861)US 11478533
- May 13, 2040method-of-use (U-3861)US 11478533
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 12396953
- Feb 1, 2039formulationUS 12396953
- Feb 1, 2039formulationUS 12396953
- Feb 1, 2039formulationUS 12396953
- Feb 1, 2039formulationUS 12396953
- Feb 1, 2039formulationUS 12396953
- Feb 1, 2039formulationUS 12396953
- Oct 10, 2038method-of-use (U-4418)US 12029779
- Oct 10, 2038method-of-use (U-3162)US 12029779
- Oct 10, 2038method-of-use (U-2628)US 12295988
- Oct 10, 2038method-of-use (U-4418)US 12551536
- Oct 10, 2038method-of-use (U-4418)US 12551536
- Aug 24, 2038formulationUS 10888605
- Aug 24, 2038formulationUS 10888605
- Aug 24, 2038formulationUS 10888605
- Aug 24, 2038formulationUS 10888605
- Aug 24, 2038formulationUS 10888605
- Aug 24, 2038formulationUS 10888605
- Aug 24, 2038formulationUS 11752198
- Aug 24, 2038formulationUS 11752198
- Aug 24, 2038formulationUS 11752198
- Aug 24, 2038formulationUS 11752198
- Aug 24, 2038formulationUS 11752198
- Aug 24, 2038formulationUS 11752198
- Aug 24, 2038formulationUS 12214017
- Aug 24, 2038formulationUS 12214017
- Aug 24, 2038formulationUS 12214017
- Aug 24, 2038formulationUS 12214017
- Aug 24, 2038formulationUS 12214017
- Aug 24, 2038formulationUS 12214017
- Apr 28, 2037method-of-use (U-4443)US 12569543
- Apr 28, 2037method-of-use (U-4443)US 12569543
- Apr 28, 2037method-of-use (U-4443)US 12569543
- Apr 28, 2037method-of-use (U-4443)US 12569543
- Apr 28, 2037method-of-use (U-4443)US 12569543
- Apr 28, 2037method-of-use (U-4443)US 12569543
- Apr 28, 2037method-of-use (U-4446)US 12569543
- Apr 28, 2037method-of-use (U-4446)US 12569543
- Apr 28, 2037method-of-use (U-4446)US 12569543
- May 2, 2034method-of-use (U-4389)US 10278923
- May 2, 2034method-of-use (U-4389)US 10278923
- May 2, 2034method-of-use (U-4389)US 10278923
- May 2, 2034method-of-use (U-4389)US 10278923
- May 2, 2034method-of-use (U-2628)US 10278923
- May 2, 2034method-of-use (U-2628)US 10278923
- May 2, 2034method-of-use (U-2628)US 10278923
- May 2, 2034compositionUS 10278923
- May 2, 2034compositionUS 10278923
- May 2, 2034compositionUS 10278923
- May 2, 2034method-of-use (U-4388)US 12239739
- May 2, 2034compositionUS 12239739
- May 2, 2034compositionUS 12239739
- May 2, 2034compositionUS 12239739
- May 2, 2034compositionUS 12239739
- May 2, 2034compositionUS 12239739
- May 2, 2034compositionUS 12239739
- May 2, 2034method-of-use (U-4388)US 12239739
- May 2, 2034method-of-use (U-4388)US 12239739
- May 2, 2034method-of-use (U-4388)US 12239739
- May 2, 2034method-of-use (U-2628)US 12514822
- May 2, 2034method-of-use (U-2628)US 12514822
- May 2, 2034method-of-use (U-2628)US 12514822
- May 2, 2034method-of-use (U-2628)US 12514822
- May 2, 2034method-of-use (U-2628)US 12514822
- May 2, 2034method-of-use (U-2628)US 12514822
- Jun 21, 2033formulationUS 10335462
- Jun 21, 2033method-of-use (U-2580)US 10335462
- Jun 21, 2033method-of-use (U-2580)US 10335462
- Jun 21, 2033method-of-use (U-3161)US 9764003
- Jun 21, 2033method-of-use (U-3161)US 9764003
- Jun 21, 2033method-of-use (U-3161)US 9764003
- Jun 21, 2033method-of-use (U-3161)US 9764003
- Jun 21, 2033method-of-use (U-4418)US 9764003
- Jun 21, 2033method-of-use (U-3161)US 9764003
- Mar 15, 2033formulationUS 10933120
- Mar 15, 2033formulationUS 10933120
- Mar 15, 2033formulationUS 10933120
- Mar 15, 2033formulationUS 11759501
- Mar 15, 2033formulationUS 11759501
- Mar 15, 2033formulationUS 11759501
- Mar 15, 2033formulationUS 11759502
- Mar 15, 2033formulationUS 11759502
- Mar 15, 2033formulationUS 11759502
- Mar 15, 2033formulationUS 11759503
- Mar 15, 2033formulationUS 11759503
- Mar 15, 2033formulationUS 11759503
- Dec 16, 2031formulationUS 10086047
- Dec 16, 2031formulationUS 10086047
- Dec 16, 2031formulationUS 10086047
- Dec 16, 2031formulationUS 10960052
- Dec 16, 2031formulationUS 10960052
- Dec 16, 2031formulationUS 10960052
- Dec 16, 2031compositionUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031compositionUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031compositionUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031formulationUS 9278123
- Dec 16, 2031compositionUS 9278123
- Dec 16, 2031formulationUS 9278123
- Dec 16, 2031formulationUS 9278123
- Dec 16, 2031formulationUS 9278123
- Dec 16, 2031formulationUS 9278123
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
FDA exclusivities (29)
- Dec 22, 2028NPNP2.1y
- Dec 22, 2028NPNP2.1y
- Dec 22, 2028NPNP2.1y
- Dec 22, 2028NPNP2.1y
- Oct 17, 2028I-976Indication (3y)1.9y
- Oct 17, 2028I-976Indication (3y)1.9y
- Oct 17, 2028I-976Indication (3y)1.9y
- Oct 17, 2028I-976Indication (3y)1.9y
- Oct 17, 2028I-976Indication (3y)1.9y
- Oct 17, 2028I-976Indication (3y)1.9y
- Aug 15, 2028I-973Indication (3y)1.7y
- Aug 15, 2028I-973Indication (3y)1.7y
- Aug 15, 2028I-973Indication (3y)1.7y
- Aug 15, 2028I-973Indication (3y)1.7y
- Aug 15, 2028I-973Indication (3y)1.7y
- Jan 28, 2028I-961Indication (3y)1.2y
- Jan 28, 2028I-961Indication (3y)1.2y
- Jan 28, 2028I-961Indication (3y)1.2y
- Jan 28, 2028I-961Indication (3y)1.2y
- Mar 8, 2027I-935Indication (3y)109d
- Mar 8, 2027I-935Indication (3y)109d
- Mar 8, 2027I-935Indication (3y)109d
- Mar 8, 2027I-935Indication (3y)109d
- Mar 8, 2027I-935Indication (3y)109d
- Mar 8, 2027I-935Indication (3y)109d
- Mar 8, 2027I-935Indication (3y)109d
- Mar 8, 2027I-935Indication (3y)109d
- Mar 8, 2027I-935Indication (3y)109d
- Jul 21, 2026D-190New Indication (3y)
News(10)
- ‘Selling and marketing snake oil’: The debate over compounded GLP-1sProponents of compounding argue it increases access, lowers prices and helps patients who may need individualized versions of a drug. But there are serious concerns, experts said at the HLTH confer…biopharma_dive · 10h ago
- Novo’s consumer push gains momentum with Wegovy pill, CagriSema on deckLAS VEGAS — When Ed Cinca returned to Novo after four years away, he barely recognized the place. “I think the building’s the same, but that’s about it,” Cinca, Novo’s senior vice president of mark…endpoints · 10h ago
- STAT+: Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and moreThe FDA approved a breast cancer drug from Roche, teeing up the launch of what the company has said could become its top-selling productstat · 1d ago
- STAT+: Newer GLP-1 drugs to combat obesity may be the next global battleground over access to medicines, expert warnsHow obesity medications may become the next big battleground over access to medicines in lower-income countries.stat · 2d ago
- Novo’s CagriSema drives more than 20% weight loss at lower dosesAs Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed in…biospace · 2d ago
- Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persist…biospace · 5d ago
- Blackstone bets $1.5B on Pfizer’s obesity drugThe deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.biopharma_dive · 6d ago
- Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked NovemberNovartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about th…biospace · 7d ago
- STAT+: Pharmalittle: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and moreThe FDA approved a novel drug to reduce recurrence of stroke, the agency is warning that GLP-1s carry a potential risk for an eye condition, and more pharma news of…stat · 8d ago
- Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorderHaving linked its glucagon/GLP-1 candidate to a significant reduction in heavy drinking days, Altimmune is preparing to speak to the FDA in December about the design of a Phase 3 program.biospace · 8d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that